Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Global Clinical Leader
Daiichi Sankyo
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
284 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal Adelaide Hospital
Adelaide, Australia
- Flinders Medical Centre (fmc)
Bedford Park, Australia
- Flinders Medical Centre (fmc)
Bedford Park, Australia
- Box Hill Hospital
Box Hill, Australia
- Concord Repatriation General Hospital
Concord, Australia
- St Vincent'S Hospital Melbourne
Darlinghurst, Australia
- Townsville University Hospital
Douglas, Australia
- Liverpool Hospital
Liverpool, Australia
- the Alfred Hospital
Melbourne, Australia
- Fiona Stanley Hospital
Murdoch, Australia
- Sir Charles Gairdner Hospital
Perth, Australia
- Princess Alexandra Hospital
Woolloongabba, Australia
- Ordensklinikum Linz Gmbh - Elisabethinen
Linz, Austria
- Lkh - Universitätsklinikum Der Pmu Salzburg
Salzburg, Austria
- Hanusch Krankenhaus Der Wgkk Wien
Vienna, Austria
- Institut Jules Bordet
Anderlecht, Belgium
- Zna
Antwerp, Belgium
- Az Sint-Jan
Bruges, Belgium
- Cliniques Universitaires Saint-Luc
Brussels, Belgium
- Uz Leuven
Leuven, Belgium
- Chu de Liage
Liège, Belgium
- Az Delta
Roeselare, Belgium
- Cetus Hospital Dia Oncologia
Belo Horizonte, Brazil
- Unesp - Faculdade de Medicina Da Universidade Estadual Paulista - Campus Botucatu
Botucatu, Brazil
- Centro de Hematologia E Hemoterapia - Hemocentro de Campinas - Unicamp
Campinas, Brazil
- Hospital Erasto Gaertner - Liga Paranaense de Combate Ao Câncer
Curitiba, Brazil
- Cepon - Centro de Pesquisas Oncolagicas de Santa Catarina
Florianópolis, Brazil
- Huwc - Ufc - Hospital Universitário Walter Cantídio - Universidade Federal Do Ceará
Fortaleza, Brazil
- Hc-Ufg - Hospital Das Clínicas Da Universidade Federal de Goiás
Goiânia, Brazil
- Fundacao Doutor Amaral Carvalho
Jaú, Brazil
- Hospital de Clínicas de Passo Fundo
Passo Fundo, Brazil
- Hospital de Clănicas de Porto Alegre
Porto Alegre, Brazil
- Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, Brazil
- Inca - Instituto Nacional de Cancer
Rio de Janeiro, Brazil
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
Sao Jose Rio Preto, Brazil
- Hospital Beneficencia Portuguesa Da Sao Paulo
São Paulo, Brazil
- Hospital Nove de Julho
São Paulo, Brazil
- Icesp - Instituto Do Câncer Do Estado de São Paulo Octavio Frias de Oliveira
São Paulo, Brazil
- Sírio-Libanês Brasilia-Centro de Oncologia-Asa Sul
São Paulo, Brazil
- Umhat 'Dr. Georgi Stranski', Ead
Pleven, Bulgaria
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Nov 2024
- Primary completion
- 26 Jun 2030
- Completion
- 26 Jun 2030
- Last update posted
- 2 Jul 2026
- Registered enrollment
- 700
- Registry id
- NCT06578247
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.